Avivagen Announces U.S. Product Launch of Vivamune
09 Julho 2013 - 9:00AM
Access Wire
OTTAWA, ONTARIO, July 9, 2013 - Avivagen Inc. (TSXV:VIV), a
wellness company developing and delivering products that support
and enhance the health and quality of life for animals and the
people who care for them, announces its United States launch of
Vivamune(TM) Health Chews for dogs.
Avivagen is pleased to announce the launch of its latest product
- Vivamune(TM) Health Chews for dogs. As of today, U.S. pet parents
have direct access to this exciting new canine health supplement.
The proprietary ingredients in Vivamune(TM) Health Chews have been
shown to act on the immune system and may thereby support healthy
skin, coat and gut and help to maintain normal mobility. This
science-based and highly-palatable natural chew is intended to help
dogs lead long and healthy lives.
An advertisement supporting Vivamune(TM) Health Chews can be
viewed in the current newsstand and online editions of Animal
Wellness magazine. The campaign headline "For dogs that dig life"
is intended to convey the love that people feel for their dogs and
the benefits to their living long and healthy lives. U.S. pet
parents can order Vivamune(TM) Health Chews for their dogs online
at www.vivamunehealth.com.
Dave Hankinson, Executive Director of Avivagen commented on this
important milestone, "It is exciting to be able to broaden access
to Avivagen's health discoveries through our latest product. This
is the result of work by our staff and external collaborators and
we thank them for their dedication."
Cameron Groome, CEO and President of Avivagen offered his own
perspective "The launch of Vivamune(TM) Health Chews for dogs
executes one more of our stated corporate goals and provides a
further source of revenues for Avivagen. In the coming quarters we
will continue to drive sales of our three commercial products,
Vivamune(TM) Health Chews, Oximunol(TM) Chewable Tablets and
OxC-beta for livestock."
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading
on the TSX Venture Exchange under the ticker symbol "VIV". The
Company's goal is to develop and deliver scientifically-proven
solutions that can truly benefit companion and production animals
by employing natural mechanisms for maintaining good health.
Avivagen's targeted markets include Pet Wellness and Livestock
Productivity.
The company has sites located in partnership facilities of the
National Research Council of Canada (NRC) - in Ottawa, Ontario and
Charlottetown, Prince Edward Island.
More information can be found at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology is based
on its discoveries concerning carotenoid antioxidants. The novel
natural compounds discovered by Avivagen support the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's commercial-stage application of its
technology is Fully-Oxidized beta-Carotene (OxC-beta).
OxC-beta compounds occur naturally as carotenoid oxidation
products in vegetation, but in minute amounts. They have been
developed to support the health of companion animals and for use in
the global food animal market.
Research results indicate OxC-beta supports innate immune
function, which can help maintain good health. In pets, OxC-beta
supports overall vitality and energy, mobility and joint function,
skin, coat and gut. Results observed in food animals have included
healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are Oximunol(TM) Chewables,
OxC-beta for livestock and now Vivamune(TM) Health Chews.
About Vivamune(TM) Health Chews - "For dogs that dig life"
Vivamune(TM) Health Chews are scientifically-formulated
bone-shaped chews for dogs that contain Avivagen's proprietary
active ingredients. Vivamune(TM) Health Chews work with a dog's own
immune system to maintain overall health and well-being. They are
sold in re-sealable packages of 30 chews and are currently
available in the United States by ordering on-line at
www.vivamunehealth.com.
About Oximunol(TM) Chewables - "Optimized Health in a Chewable
Tablet"
Oximunol(TM) Chewables are scientifically-formulated chewable
tablets that contain Avivagen's proprietary, patented active
ingredient OxC-beta. OxC-beta has been shown to stimulate innate
cellular immunity and may thereby help to maintain overall health
and well-being. Oximunol(TM) Chewables are available through
veterinarians for dogs of all ages in the United States.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0
or 5.0 Kg quantities for parts-per-million addition to animal
feeds, in accordance with producer-developed protocols. In past
studies, OxC-beta has been shown to support health and growth in
species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
Forward Looking Statements
This news release includes certain forward-looking statements that
are based upon current expectations, which involve risks and
uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", and similar expressions. The forward-looking
statements reflect the current expectations of Avivagen Inc.
regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from
current expectations. Avivagen assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking
statements.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024